

Bridges to Understanding SYLLABUS

Allergy, Asthma & Immunologic Disorders

Saturday, April 28, 2018

InterContinental San Francisco, California

Jointly Sponsored by The Allergy, Asthma, and Immunology
Foundation of Northern California and the University at Buffalo
Jacobs School of Medicine and Biomedical Sciences

Twenty-Seventh Annual Educational Symposium
Allergy, Asthma & Immunologic Disorders

April 28, 2018

Dear Conference Participant:

Welcome to Bridges to Understanding, the 27th Annual Educational Symposium presented by the Allergy, Asthma, and Immunology Foundation of Northern California. We believe that this annual conference is among the best-attended single-day Allergy/Immunology educational symposia in the nation. The goal of this conference is to provide physicians and allied healthcare professionals with current, concise, and clinically useful information essential to optimizing the care of patients with asthma, allergies, and other immunologic disorders.

We have a great Symposium for you this year featuring six outstanding speakers. They will cover an array of topics: a Mini Symposium on Pruritic rashes, new horizons on food allergy treatments, current concepts in IgG4-related diseases, and Pediatric Asthma.

Please take a moment to visit the displays of each of our exhibitors during the scheduled refreshment and lunch breaks. We greatly appreciate their support.

We hope you will enjoy today's conference and find it both intellectually stimulating and helpful to your practice. Thank you for your attendance.

Sincerely,

Steve Machtinger, MD; Board President

CONTINUING MEDICAL EDUCATION INFORMATION

Educational Objectives

At the conclusion of this program, the participant will be able to:

<ul style="list-style-type: none">• Select appropriate patients for biologic therapy
<ul style="list-style-type: none">• Select appropriate patients for biologic and immunosuppressive therapies
<ul style="list-style-type: none">• Accurately interpret results of patch testing
<ul style="list-style-type: none">• Enhance patient outcomes in cases of contact dermatitis
<ul style="list-style-type: none">• Understand genetic, epigenetic & environmental factors leading to the development of pediatric asthma• Select appropriate patients for referral to university-based food oral immunotherapy studies• Understand and use early intervention strategies for preventing the development of food allergy in infants• Describe clinical manifestations of IgG4-related disease and understand how the diagnosis is made
<ul style="list-style-type: none">• Implement the latest recommendations for treatment and management of IgG4-related disease.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University at Buffalo Jacobs School of Medicine and Biomedical Sciences and the Allergy, Asthma, and Immunology Foundation of Northern California (AAIFNC).

Credit Designation Physicians: The University at Buffalo Jacobs School of Medicine and Biomedical Sciences is accredited by the ACCME to provide continuing medical education for physicians.

CERTIFICATION: The University of Buffalo Jacobs School of Medicine & Biomedical Sciences designates this live activity for a maximum of **6.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-Physicians: A Certificate of Attendance can be obtained for your participation and submitted to your professional organization for determination of credits.

To receive CME credit, please:

1. To request your certificate, please visit our website at www.aaifnc.org and click on the CME link.
2. Complete the required information and AAIFNC will email your certificate.

Disclaimer

The information provided at this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The educational content from this symposium may not be used without permission.

AAIFNC 2018 Executive Board of Directors

Steven Machtinger, MD; President

Josh Jacobs, MD; Vice-President, Conference Chair

Kristina H. Philpott, MD; Treasurer

Alan Goldsobel, MD; Secretary

Anita Carmen Choy, MD; Autumn Guyer, MD; Russell Leong, MD; Sean Austin McGhee, MD; Mike Reid, MD

The Allergy, Asthma, & Immunology Foundation of Northern California is a non-profit organization dedicated to promoting knowledge and understanding of allergy, asthma and clinical immunology through advocacy and education. All proceeds from this program will be used to achieve these goals.

Bridges to Understanding Faculty Disclosures

AAIFNC endorses the guidelines for accredited continuing medical education programs as set forth in the ACCME's *Standards for Commercial Support of Continuing Medical Education* and adheres to them in the conduct of its educational programs and the selection of topics and presenters.

A full disclosure of proprietary interests is required of all presenters and faculty members and the presence of any relationship is reported to all program attendees on the presentation slides. Even with disclosure, presentations should not promote use of a commercial product. Faculty members are encouraged to use generic, rather than trade drug names, in conjunction with this educational activity. In addition, multiple drugs and/or therapies should be discussed whenever it is appropriate to do so. Any discussion of unlabeled uses of products regulated or still under investigation of the FDA must be disclosed as such to the audience.

AAIFNC is committed to the advancement of knowledge and science in allergy, asthma and immunology.

MATTHEW BAKER, MD – No conflicts

MARK BOGUNIEWICZ, MD

Grant/Research Support: Regeneron

Consultant: Regeneron, Sanofi-Genzyme, Pfizer

Speakers' Bureau: Regeneron, Sanofi-Genzyme

MATTHEW GREENHAWT, MD

Grant/Research Support: PI for K08-HS024599 (Agency for Healthcare Quality and Research, to the University of Colorado; DBV BIOPOT Study (to the University of Colorado

Consultant: Thermo Fisher, Aimmune, Intrommune, Canadian Transportation Agency, Forsythe Capital

Speakers' (CME/Non CME): Thermo Fisher, Symbiotix, Hybrid Health, Clinical Mind, Vindico, Before Brands, ACAAI, Allergy and Asthma Network, State/local allergy society talks (NY, PA, KY, Western, Swineford, Kansas City, Aspen)

Paid Advisory Boards: Monsanto, Hybrid Health, Aimmune, Kaleo, Nutricia, Symbiotix

Other (non-financial): Member, Joint Task Force on Allergy Practice Parameters; Member, CSACI Food Allergy in Schools Guideline Panel; Member of the Medical Advisory Team for the Allergy and Asthma Foundation of America and the International Association for Food Protein; Enterocolitis; Member of AAAAI EGID, Anaphylaxis, Adverse Reaction to Food committees; Co-chair, AAAAI Primary Prevention of Food Allergy Working Group; Co-chair, AAAAI Oral Immunotherapy Office-based Practice Working Group; Member ACAAI Annual Meeting Planning Committee, Chair, GI/Food Allergy Track chair; Chair, Food Allergy Committee; ACAAI representative to consensus statement on interim consensus on early peanut introduction guidelines; Member, NIAID Expert Panel on early introduction of peanut to prevent peanut allergy; Associate Editor, Annals of Allergy, Asthma, and AC Immunology; Editorial board: Allergy and Immunology; Medscape Pediatrics; Infectious Diseases in Children; Member, Scientific Advisory Council National Peanut Board; Member, EAACI Task Force on Nutrition and Immunomodulation

FERNANDO MARTINEZ, MD

Grant/Research Support: NIH/NHLBI; NIH/NIEHS; NIH/NIAID; NIH, Office of Director; Johnson & Johnson

Consultant: Copeval; Commense, Inc.

JENNY MURASE, MD

Consultant: Dermira, UCB, UpToDate, Medscape

MARC RIEDL, MD

Grant/Research Support: BioCryst; CSL Behring; Pharming; Shire

Consultant: Adverum; Alnylam; BioCryst; CSL Behring; Kalvista; Pharming; Shire

Speakers' Bureau: CSL Behring; Pharming; Shire

The following companies have provided funds to exhibit at this symposium:

Accredo Health Group
ALK Pharma
AstraZeneca
Boehringer-Ingelheim
Circassia
CSL Behring, LLC
Genentech/Novartis (Xolair)
GlaxoSmithKline
Horizon Pharmaceuticals
Kaleo
Optinose
Regeneron
Shire
Stallergenes Greer
TEVA

We extend our sincere appreciation for the support of these organizations. Please take time to view the displays and visit with the pharmaceutical representatives.

Please Note: the Allergy, Asthma, and Immunology Foundation of Northern California seeks funding from companies with competing products; these companies have no input or control over the program content or the selection of the faculty.

The educational content from this symposium may not be used without permission.